Benitec Biopharma Price to Sales Ratio 2014-2022 | BNTC
Historical PS ratio values for Benitec Biopharma (BNTC) over the last 10 years. The current P/S ratio for Benitec Biopharma as of May 27, 2022 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Benitec Biopharma P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2022-05-27 |
1.01 |
|
0.53 |
| 2022-03-31 |
2.34 |
$1.89 |
1.24 |
| 2021-12-31 |
2.62 |
$0.76 |
3.45 |
| 2021-09-30 |
3.57 |
$0.18 |
19.70 |
| 2021-06-30 |
4.25 |
$9.35 |
0.45 |
| 2021-03-31 |
5.17 |
$2.20 |
2.35 |
| 2020-12-31 |
3.00 |
$7.34 |
0.41 |
| 2020-09-30 |
6.28 |
$7.29 |
0.86 |
| 2020-06-30 |
7.91 |
$5.80 |
1.36 |
| 2020-03-31 |
3.93 |
$14.05 |
0.28 |
| 2019-12-31 |
5.10 |
$17.85 |
0.29 |
| 2019-09-30 |
7.11 |
$17.85 |
0.40 |
| 2017-09-30 |
21.70 |
$10.18 |
2.13 |
| 2016-09-30 |
14.00 |
$8.99 |
1.56 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.008B |
$0.000B |
|
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
|
